NCT07434752

Brief Summary

The goal of this study is to evaluate the influence of consuming a drink containing a combination of caffeine and green tea extracts on fat oxidation responses at rest, during and after a period of endurance type exercise.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
5mo left

Started Mar 2026

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress33%
Mar 2026Dec 2026

First Submitted

Initial submission to the registry

January 5, 2026

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 27, 2026

Completed
27 days until next milestone

Study Start

First participant enrolled

March 26, 2026

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

April 16, 2026

Status Verified

January 1, 2026

Enrollment Period

8 months

First QC Date

January 5, 2026

Last Update Submit

April 13, 2026

Conditions

Keywords

metabolism

Outcome Measures

Primary Outcomes (1)

  • Fat oxidation as measured by indirect calorimetry

    Change from baseline to the end of the study period in Fat oxidation as measured by indirect calorimetry (metabolic cart); baseline (pre-drink), post-drink (pre-exercise), time sequence e.g., every 5-min during exercise, 10, 20 and 30-min post-exercise. Change from baseline \& total. Fat oxidation will be measured continuously throughout the exercise and the 30-min post-exercise window, to facilitate total, and any other temporal fat oxidation timepoints.

    Baseline to 30 mins post exercise

Secondary Outcomes (3)

  • Carbohydrate oxidation; indirect calorimetry

    Baseline to 30 mins post exercise

  • Respiratory exchange ratio; indirect calorimetry

    Baseline to 30 mins post exercise

  • Exercise efficiency; indirect calorimetry

    Baseline to 30 mins post exercise

Other Outcomes (11)

  • Tertiary: Compliance monitoring

    Baseline to end of study period (week 5)

  • Tertiary: Adverse Event monitoring

    Baseline to end of study period (week 5)

  • Tertiary: Perceived gastrointestinal (dis)comfort questionnaire

    Baseline to end of study (week 5)

  • +8 more other outcomes

Study Arms (2)

Active

EXPERIMENTAL

Two 355 mL cans of "XS Energy + BURN" drink containing caffeine and green tea extract.

Dietary Supplement: Active (Green tea and caffeine)

Placebo

OTHER

Two 355 mL cans of placebo drink but without the active ingredients (caffeine and green tea extract).

Other: Placebo

Interventions

Two 355 mL cans of "XS Energy + BURN" drink containing caffeine and green tea extract.

Also known as: XS Energy + BURN
Active
PlaceboOTHER

Two 355 mL cans of placebo drink but without the active ingredients (caffeine and green tea extract).

Placebo

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Passing the Exercise and Sport Science Australia adult pre-exercise screening system (APSS) stage 1 \& 2 (see appendix 4).
  • Between the ages of 18 and 45,
  • Not sedentary, and not completing more than 150 minutes of low and/or moderate and/or or vigorous intensity endurance exercise a week,
  • Ability to commit to in principle fulfilment of all 3 trial visits,
  • No history of coagulopathy e.g., DVT, stroke,
  • No known heart disease,
  • No known pancreatic insufficiency,
  • No known inflammatory bowel disease, or prior bowel resection or bypass surgery (excluding gastric banding and sleeve),
  • BMI of 22.0 to 34.9 kg/m2,
  • No known allergies to caffeine or green tea extract,
  • No known type I or II diabetes,
  • No uncontrolled concurrent illness,
  • No known current pregnancy or breastfeeding women
  • No current regular consumption of supplements (\>2 times a week) or foods and drinks containing caffeine and/or green tea extracts (\>2 times per day, weekly).
  • Agree not to consume caffeine for 12-hours prior to the clinic visit.

You may not qualify if:

  • Under the age of 18 or over the age of 45,
  • Sedentary, or completing over 150 minutes of low and/or moderate and/or or vigorous intensity endurance exercise a week,
  • Inability to commit to in principle fulfilment of all 3 trial visits,
  • History of coagulopathy e.g., DVT, stroke,
  • Known heart disease,
  • Known pancreatic insufficiency,
  • Known inflammatory bowel disease, or prior bowel resection or bypass surgery (excluding gastric banding and sleeve),
  • BMI \< 22.0 or \> 34.9 kg/m2,
  • Known allergies to caffeine or green tea extract,
  • Known type I or II diabetes,
  • Uncontrolled concurrent illness,
  • Taking GLP-1 agonists, caffeine, or any other medication known to affect metabolism.
  • Known current pregnancy or breastfeeding women.
  • Currently regularly consuming supplements, foods or drinks containing a caffeine and green tea extract blend, or not willing to abstain for the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Griffith University, Gold Coast Campus

Southport, Queensland, 4222, Australia

RECRUITING

MeSH Terms

Conditions

Motor Activity

Interventions

ExerciseTeaCaffeine

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaPlant PreparationsBiological ProductsComplex MixturesBeveragesDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesXanthinesAlkaloidsHeterocyclic CompoundsPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 5, 2026

First Posted

February 27, 2026

Study Start

March 26, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

April 16, 2026

Record last verified: 2026-01

Locations